The Medical Letter on Drugs and Therapeutics
In Brief: Rosiglitazone (Avandia) Unbound
Download PDF:   US English
Med Lett Drugs Ther. 2014 Feb 3;56(1435):12
 Select a term to see related articles  Avandia   drug safety   metformin   Rosiglitazone   Sulfonylureas 

The FDA has removed prescribing and dispensing restrictions placed on rosiglitazone (Avandia, and others) in 2010 because of concerns about its cardiovascular safety.1 The removal of restrictions was based on the results of an independent reevaluation of the RECORD trial, which found no significant difference between rosiglitazone and metformin/sulfonylurea in the risk of cardiovascular (or unknown cause) death, myocardial infarction, or stroke.2

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article